Final height in short polytransfused thalassemia major patients treated with recombinant growth hormone

We measured the final height (FH) of 25 short polytransfused thalassemia major (Th) patients (18 males) with a reduced GH reserve treated for 3.3 +/- 1.2 yr with recombinant GH (rhGH), 0.2 mg/kg/week sc. At baseline, all patients were clinically prepubertal; their chronological (CA) and bone ages (B...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of endocrinological investigation 2005-04, Vol.28 (4), p.363-366
Hauptverfasser:	Cavallo, L, De Sanctis, V, Cisternino, M, Caruso Nicoletti, M, Galati, M C, Acquafredda, A, Zecchino, C, Delvecchio, M
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent beta-Thalassemia - complications beta-Thalassemia - drug therapy Body Height Child Drug Administration Schedule Female Human Growth Hormone - pharmacology Human Growth Hormone - therapeutic use Humans Male Puberty Recombinant Proteins
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!